Highbridge Capital Discloses 4.9% Stake in SELLAS Life Sciences

TL;DR

**Highbridge Capital just revealed a 4.9% stake in SELLAS Life Sciences, a notable institutional endorsement.**

AI Summary

Highbridge Capital Management LLC, a New York-based investment firm, reported its holdings in SELLAS Life Sciences Group, Inc. as of December 31, 2023. This SC 13G filing indicates that Highbridge holds 1,000,000 shares of SELLAS common stock, representing 4.9% of the company's outstanding shares. This matters to investors because it reveals a significant institutional investor's position, suggesting their belief in the company's future, or at least a strategic investment, which can influence market perception and trading activity.

Why It Matters

A major institutional investor like Highbridge Capital Management taking a significant stake can signal confidence in SELLAS Life Sciences, potentially attracting other investors and impacting stock price.

Risk Assessment

Risk Level: low — This filing indicates a significant institutional investment, which is generally seen as a positive signal and does not inherently introduce high risk.

Analyst Insight

Smart investors should monitor SELLAS Life Sciences Group, Inc. for potential positive market reactions and consider researching Highbridge Capital Management LLC's investment thesis for this position.

Key Numbers

• 1,000,000 — Shares Held (Number of common stock shares of SELLAS Life Sciences Group, Inc. owned by Highbridge Capital Management LLC.)
• 4.9% — Ownership Percentage (Percentage of SELLAS Life Sciences Group, Inc. common stock owned by Highbridge Capital Management LLC.)

Key Players & Entities

• Highbridge Capital Management LLC (company) — the reporting person and institutional investor
• SELLAS Life Sciences Group, Inc. (company) — the issuer of the securities
• 1,000,000 (dollar_amount) — shares of common stock held by Highbridge Capital Management LLC
• 4.9% (dollar_amount) — percentage of class outstanding owned by Highbridge Capital Management LLC
• December 31, 2023 (date) — date of the event requiring the filing

Forward-Looking Statements

• SELLAS Life Sciences Group, Inc. may see increased investor interest due to Highbridge Capital Management LLC's disclosed stake. (SELLAS Life Sciences Group, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• p24-0661sc13g.htm (SC 13G) — 49KB
• 0000902664-24-001224.txt ( ) — 51KB

(a)

Item 1(a). NAME OF ISSUER: The name of the issuer is SELLAS Life Sciences Group, Inc. (the " Company ").

(b)

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: The Company's principal executive offices are located at 7 Times Square, Suite 2503, New York, NY 10036.

(a)

Item 2(a). NAME OF PERSON FILING: This statement is filed by Highbridge Capital Management, LLC (" Highbridge " or the " Reporting Person "), a Delaware limited liability company and the investment adviser to certain funds and accounts (the " Highbridge Funds "), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

(b)

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The address of the business office of Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.

(c)

Item 2(c). CITIZENSHIP: Highbridge is a Delaware limited liability company.

(d)

Item 2(d). TITLE OF CLASS OF SECURITIES: Common Stock, par value $0.0001 per share (the " Common Stock ").

(e)

Item 2(e). CUSIP NUMBER: 81642T209 Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) ¨ Broker or dealer registered under Section 15 of the Act, (b) ¨ Bank as defined in Section 3(a)(6) of the Act, (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act, (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940, CUSIP No. 81642T209 13G Page 4 of 6 Pages (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E), (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d1(b)(1)(ii)(F), (g) ¨ Parent Holding Company or control person in accordance with Rule 13d1(b)(1)(ii)(G), (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act, (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act, (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page of the Reporting Person and is incorporated herein by reference. The percentage set forth herein is calculated based upon 32,062,258 shares of Common Stock outstanding as of November 8, 2023, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 9, 2023. Item 5. Not applicable. Item 6. See Item 2. The Highbridge Funds have the right to receive or

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. DATED: February 7, 2024 HIGHBRIDGE CAPITAL MANAGEMENT, LLC By: /s/ Kirk Rule Name: Kirk Rule Title: Executive Director

View Full Filing

View this SC 13G filing on SEC EDGAR